



BIODIEM LTD
ABN 20 096 845 993
Level 10, South Tower,
459 Collins Street,
Melbourne, Victoria, 3000
Australia
www.biodiem.com

ASX Announcement

BioDiem receives further licence fees for LAIV influenza vaccine.

Melbourne, 8 May 2012: Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced receipt of licence fees of US\$844,000 under existing licence agreements for its LAIV influenza vaccine. This brings the total revenue from LAIV licensing to US\$1.4 million for the financial year to date.

BioDiem looks forward to being able to meet the growing demand for influenza vaccines in the future through further licencing of the LAIV influenza vaccine.

"Building the revenue stream from our vaccine licensing work is a key objective for BioDiem, and we are pleased to announce an increase in these cash flows" said BioDiem Chief Executive Officer Julie Phillips.

"Increasing the availability of the LAIV intranasal vaccine will help increase vaccination uptake, especially in children, and lower the number of preventable deaths from influenza".

As well as working to expand its vaccine licensing business, BioDiem continues to advance its product and technology portfolio with the aim of developing further technologies for the prevention and treatment of other significant infectious diseases.

ENDS

About BioDiem Ltd

BioDiem is an ASX-listed company based in Melbourne with an international focus on discovering, developing and commercialising world-class research and technology for the prevention and treatment of infectious diseases. BioDiem's core technologies derive from its expertise with the Live Attenuated Influenza Virus (LAIV), which is an intranasal vaccine to prevent infection from seasonal and pandemic influenza.

BioDiem is also developing non-LAIV-related assets including BDM-I, a synthetic compound active against a range of pathogenic micro-organisms including gram-positive and gram-negative bacteria, fungi and protozoa. Key patents have been filed around BDM-I's antimicrobial action. BDM-I is being developed for the treatment of serious human infections with outlicensing as the intended outcome.

About LAIV Technology

The Live Attenuated Influenza Virus (LAIV) vaccine was in-licensed from the Institute of Experimental Medicine in St Petersburg, Russia, where it has been approved and used in its present form for over a decade in many millions of people - children, adults and the elderly.

LAIV vaccine is administered by nasal spray and induces a rapid immune response in the mucosal lining of the nose and pharynx. The vaccines are based on 'Master Donor Strains' that have been rendered 'cold adapted' and temperature sensitive, such that they will not replicate readily at temperatures above 33°C, as found in the lungs. The administration of the live vaccine stimulates mucosal, cellular and humoral immune responses (which are required to optimise the effective prevention of influenza), without causing the disease.

For additional information, please visit www.biodiem.com

Contact

Investors

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9613 4100
Email jphillips@biodiem.com

Media

Tom Donovan
Buchan Consulting
Phone +61 3 8866 1224 / +61 422 557 107
Email tdonovan@buchanwe.com.au